The DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.
Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence
Open accessAbstract
Immunotherapies play critical roles in cancer treatment. However, given that only a few patients respond to immune checkpoint blockades and other immunotherapeutic strategies, more novel technologies are needed to decipher the complicated interplay between tumor cells and the components of the tumor immune microenvironment (TIME). Tumor immunomics refers to the integrated study of the TIME using immunogenomics, immunoproteomics, immune-bioinformatics, and other multi-omics data reflecting the immune states of tumors, which has relied on the rapid development of next-generation sequencing. High-throughput genomic and transcriptomic data may be utilized for calculating the abundance of immune cells and predicting tumor antigens, referring to immunogenomics. However, as bulk sequencing represents the average characteristics of a heterogeneous cell population, it fails to distinguish distinct cell subtypes. Single-cell-based technologies enable better dissection of the TIME through precise immune cell subpopulation and spatial architecture investigations. In addition, radiomics and digital pathology-based deep learning models largely contribute to research on cancer immunity. These artificial intelligence technologies have performed well in predicting response to immunotherapy, with profound significance in cancer therapy. In this review, we briefly summarize conventional and state-of-the-art technologies in the field of immunogenomics, single-cell and artificial intelligence, and present prospects for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Single‐cell‐based technologies have enabled a better dissection of the TME through precise monitoring of cell sub‐populations and spatial architecture, thus revealing the heterogeneous and complex nature of the TME [10, 12].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 1×
“58,59 60 – 62 However, regarding false positivity or false negativity, none of these tools is satisfactory in all aspects.”
BackgroundPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“50,51 55 – 57 Regarding liquid tumor analysis, Strelka2 introduces a normal sample contamination model to improve the variant calling accuracy and functions fairly well in the computing cost.”
BackgroundA global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022 · cited 1×
“84,85 However, considering the complexity of the HLA types, we still expect independent benchmarking studies and more tools to be presented.”
BackgroundThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224 · cited 1×
“30 QuanTIseq is designed speci-fi cally for RNA-seq data, and the analysis pipeline comprises raw RNA-seq data preprocessing, gene expression quanti fi cation, and constrained least squares regression-based deconvolution.”
MethodSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“As a target of ICB, the PD-L1 expression level detected by IHC was the fi rst discovered prediction biomarker, 217 but several clinical trials have revealed moderate ef fi cacy of ICB in patients with high PD-L1 expression.”
BackgroundInferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · cited 1×
“27 The ESTIMATE score can differentiate the tumor and stomal components but cannot distinguish speci fi c immune cell types. xCell is another ssGSEA-based method that obtains gene sets to characterize distinct cell types from multiple RNA-seq and microarray-based data sources, increasing the…”
Method
Research works printed but not linked: 1
- Robinson, J. P. & Roederer, M. HISTORY OF. Sci. Flow. Cytom. strikes gold. Sci. 350, 739–740 (2015).
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Single-cell-based technologies have enabled a better dissection of the TME through precise monitoring of cell sub-populations and spatial architecture, thus revealing the heterogeneous and complex nature of the TME [10, 12].”
BackgroundArtificial Intelligence in Dermatology Image Analysis: Current Developments and Future Trends
Li, Z., Koban, K. C., Schenck, T. L., Giunta, R. E., Li, Q., & Sun, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226826 · Cited by 248
Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
Zou, J., Wang, L., Tang, H., Liu, X., Peng, F., & Peng, C. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413335 · Cited by 149
“Bioinformatics is a novel analysis technology widely used for the prediction of outcomes in cancer immunotherapy [70].”
CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer
Selvakumar, S. C., Preethi, K. A., Ross, K., Tusubira, D., Khan, M. W. A., Mani, P., Rao, T. N., & Sekar, D. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01565-1 · Cited by 139
“As a result, NGS technology has become the foundation for developing targeted immunotherapy for cancer, as well as the development of individualized treatment plans for cancer patients [42].”
Zhang, Y., Xu, M., Ren, Y., Ba, Y., Liu, S., Zuo, A., Xu, H., Weng, S., Han, X., & Liu, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01980-6 · Cited by 131
“Imaging histology, as a non-invasive imaging method, has shown great potential in the diagnosis and treatment of tumours by combining learning models with digital pathology [125].”
Method
Metadata
- Authors
- Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Xiao, Yi
- Shao, Zhi-Ming
- Jiang, Yi-Zhou
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-08-20
- Volume
- 6
- Issue
- 1
- Pages
- 312-312
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8377461
- OpenAlex
- W3194492341
- Cited by
- 163
- References
- 303
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 38 · 2023: 50 · 2022: 16 · 2021: 5
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81874113, 82002792, 81922048, 81874112)
- Fok Ying Tong Education Foundation (171034)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- cancer immunotherapy, tumor immune microenvironment, immunogenomics, immunoproteomics, single-cell analysis, artificial intelligence, radiomics, digital pathology, deep learning, immune checkpoint blockade, immunotherapy response prediction, tumor heterogeneity, immune cell subpopulations
- MeSH terms
- Antigens, Neoplasm, Artificial Intelligence, Humans, Immunity, Innate, Immunogenetics, Immunotherapy, Neoplasms, Biomarkers, Tumor, Genome, Human, Cell Lineage, Proteome, Single-Cell Analysis, Tumor Microenvironment, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence. https://app.cochat.ai/papers/10.1038/s41392-021-00729-7
- The paper
- Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021). Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00729-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.